Latest & greatest articles for colon cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colon cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colon cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colon cancer screening

1. Colon cancer screening

Colon cancer screening Top results for colon cancer screening - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might (...) look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for colon cancer screening The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical

2018 Trip Latest and Greatest

2. Organizational change: a way to increase colon, breast and cervical cancer screening in primary care practices

Organizational change: a way to increase colon, breast and cervical cancer screening in primary care practices Organizational change: a way to increase colon, breast and cervical cancer screening in primary care practices Organizational change: a way to increase colon, breast and cervical cancer screening in primary care practices Arroyave AM, Penaranda EK, Lewis CL CRD summary Organisational change interventions that circumvented the physician were most effective in increasing cancer screening (...) of organisational change interventions for cancer screening. Further research into continuous quality improvement should use the Reach Effectiveness Adoption Implementation Maintenance (RE-AIM) framework (2010). Funding American Cancer Society, USA; National Cancer Institute, USA. Bibliographic details Arroyave AM, Penaranda EK, Lewis CL. Organizational change: a way to increase colon, breast and cervical cancer screening in primary care practices. Journal of Community Health 2011; 36(2): 281-288 PubMedID DOI

2011 DARE.

3. Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening (PubMed)

Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening Preliminary studies have shown the possibility of detecting colonic polyps and tumors using the PillCam Colon capsule endoscope (CCE) (Given Imaging, Yoqneam, Israel). The aim of this study was to evaluate the ability of CCE to detect clinically relevant colonic findings (...) as compared with colonoscopy, and further, to test the assumption that CCE used in the frame of colorectal cancer (CRC) screening could accurately discriminate patients deserving a complete colonoscopy.A total of 128 patients (67 men, 55+/-14 years) with an indication of colonoscopy were investigated by CCE, followed by colonoscopy under general anesthesia on the next day. Bowel cleansing was carried out according to a previously published protocol (3 l polyethylene glycol+2 doses of sodium phosphate

2010 EvidenceUpdates

4. Tailoring Colon Cancer Screening

Tailoring Colon Cancer Screening Tailoring Colon Cancer Screening – Clinical Correlations Search Tailoring Colon Cancer Screening December 11, 2009 3 min read Guidelines for Colorectal Cancer Screening and the Recent Evidence Behind Them Nazia Hasan, MD MPH Faculty peer reviewed For most residents, screening for colorectal cancer (CRC) may seem as established as that for breast and cervical cancer. In reality, the use of CRC screening has only recently approached that of screening for those (...) . (2001). Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut ; 48: 812-815. 4. Winawer SJ, Zauber AG, O’Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. (1993). Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med ; 328: 901-906. Share: | | One comment on “ Tailoring Colon Cancer Screening ” Comments are closed. Sites We Follow

2009 Clinical Correlations

5. Tailoring Colon Cancer Screening

Tailoring Colon Cancer Screening Tailoring Colon Cancer Screening – Clinical Correlations Search Tailoring Colon Cancer Screening October 29, 2009 5 min read Guidelines for Colorectal Cancer Screening and the Recent Evidence Behind Them Nazia Hasan, MD MPH Faculty peer reviewed For most residents, screening for colorectal cancer (CRC) may seem as established as that for breast and cervical cancer. In reality, the use of CRC screening has only recently approached that of screening for those (...) England Journal of Medicine; 359 (12): 1207-1217. Levin B, et al (2008). Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008. CA Cancer J Clin . Published online March 5, 2008. United States Department of Health & Human Services (2008). US Preventative Services Task Force: Screening for Colorectal Cancer Guidelines 2008. Retrieved on July 10, 2009 from Share: | | 2 comments on “ Tailoring Colon Cancer Screening ” Comments are closed. Sites We Follow

2009 Clinical Correlations

6. CT colonography (virtual colonoscopy) for colon cancer screening

CT colonography (virtual colonoscopy) for colon cancer screening CT colonography (virtual colonoscopy) for colon cancer screening CT colonography (virtual colonoscopy) for colon cancer screening BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation BlueCross BlueShield Association. CT colonography (virtual colonoscopy) for colon cancer (...) screening. Chicago IL: BlueCross BlueShield Association (BCBS). TEC Assessment 24(1). 2009 Authors' objectives To determine whether there is adequate evidence to demonstrate that CT colonography screening is effective in reducing mortality from colon cancer. A companion Special Report will provide a critical appraisal of cost-effectiveness analyses of CT colonography. Authors' conclusions The conclusions of this Assessment rely on the generalizability of the ACRIN trial to general screening populations

2009 Health Technology Assessment (HTA) Database.

7. Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. (PubMed)

Relation between Medicare screening reimbursement and stage at diagnosis for older patients with colon cancer. Medicare's reimbursement policy was changed in 1998 to provide coverage for screening colonoscopies for patients with increased colon cancer risk, and expanded further in 2001 to cover screening colonoscopies for all individuals.To determine whether the Medicare reimbursement policy changes were associated with an increase in either colonoscopy use or early stage colon cancer (...) relative risk period 2 vs 1, 1.19; 95% confidence interval, 1.13-1.26; adjusted relative risk period 3 vs 2, 1.10; 95% confidence interval, 1.02-1.17) but weakly associated, if at all, for patients with distal colon lesions (adjusted relative risk period 2 vs 1, 1.07; 95% confidence interval, 1.01-1.13; adjusted relative risk period 3 vs 2, 0.97; 95% confidence interval, 0.90-1.05).Expansion of Medicare reimbursement to cover colon cancer screening was associated with an increased use of colonoscopy

Full Text available with Trip Pro

2006 JAMA

8. Special report: fecal DNA analysis for colon cancer screening

Special report: fecal DNA analysis for colon cancer screening Special report: fecal DNA analysis for colon cancer screening Special report: fecal DNA analysis for colon cancer screening BlueCross BlueShield Association Citation BlueCross BlueShield Association. Special report: fecal DNA analysis for colon cancer screening. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 21(6). 2006 Authors' objectives

This Special Report will provide information relevant to the evaluation (...) of fecal DNA screening for colon cancer in asymptomatic patients at average risk. This report will summarize: 1. the current context of existing and emerging screening tests for colorectal cancer, including current published recommendations;

2. the molecular basis for fecal DNA screening and the commercially available fecal DNA screening test, PreGen-Plus.;

3. direct and indirect evidence comparing the performance of PreGen-Plus. testing to other methods of colon cancer screening;

2006 Health Technology Assessment (HTA) Database.

9. Narrative review: screening for colorectal cancer in patients with a first-degree relative with colonic neoplasia. (PubMed)

Narrative review: screening for colorectal cancer in patients with a first-degree relative with colonic neoplasia. Many patients and providers are aware that colorectal cancer (CRC) "runs in families." A patient with 1 first-degree relative with CRC has approximately twice the personal risk for CRC as a similar person without this family history. Colorectal cancer is the third most common type of cancer in the United States. When providers neglect to collect information on family history (...) , they may fail to appropriately tailor recommendations for screening for CRC for many patients. This review considers the existing data and summarizes an evidence-based approach to the common clinical problem of how and when to implement screening for CRC in a patient with a family history of colonic neoplasia. The authors discuss the varying risks for CRC given the patient's age, health habits, and personal and family histories. In the context of a clinical case that focuses on the effect of a single

2005 Annals of Internal Medicine

10. CT colonography ('virtual colonoscopy') for colon cancer screening

CT colonography ('virtual colonoscopy') for colon cancer screening CT colonography ('virtual colonoscopy') for colon cancer screening CT colonography ('virtual colonoscopy') for colon cancer screening BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes (...) the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. CT colonography ('virtual colonoscopy') for colon cancer screening. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(06). 2004 Authors' objectives This Assessment reviews evidence on the effectiveness of CT colonography as an alternative to colonoscopy for the purpose of colon cancer screening. Authors' conclusions Based

2004 Health Technology Assessment (HTA) Database.

11. Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. (PubMed)

Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Colonoscopic screening for colorectal cancer has been suggested because sigmoidoscopy misses nearly half of persons with advanced proximal neoplasia.To create a clinical index to stratify risk for advanced proximal neoplasia and to identify a subgroup with very low risk in which screening sigmoidoscopy alone might suffice.Cross-sectional study.A company-based program of screening colonoscopy (...) for colorectal cancer.Consecutive persons 50 years of age or older undergoing first-time screening colonoscopy between September 1995 and June 2001.A clinical index with 3 variables was created from information on the first 1994 persons. Points were assigned to categories of age, sex, and distal findings. Risk for advanced proximal neoplasia (defined as an adenoma 1 cm or larger or one with villous histology, severe dysplasia, or cancer) was measured for each score. The index was tested on the next 1031

2003 Annals of Internal Medicine

12. [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability]

[Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability] Tecnicas endoscopicas y radiologicas en el diagnostico de cancer colo-rectal. Evaluacion de la variabilidad de uso y aceptabilidad [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability] Tecnicas endoscopicas y radiologicas en el diagnostico de cancer colo-rectal (...) . Evaluacion de la variabilidad de uso y aceptabilidad [Endoscopic and radiological techniques in the diagnosis and screening of colon cancer. Evaluation of the variability of use and acceptability] Cabriada J L, Calvo M M, Duran M, Bujanda L, Quintana J M, Iraola I Citation Cabriada J L, Calvo M M, Duran M, Bujanda L, Quintana J M, Iraola I. Tecnicas endoscopicas y radiologicas en el diagnostico de cancer colo-rectal. Evaluacion de la variabilidad de uso y aceptabilidad. [Endoscopic and radiological

2002 Health Technology Assessment (HTA) Database.

13. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. (PubMed)

One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. Fecal occult-blood testing and sigmoidoscopy have been recommended for screening for colorectal cancer, but the sensitivity of such combined testing for detecting neoplasia is uncertain. At 13 Veterans Affairs medical centers, we performed colonoscopy to determine the prevalence of neoplasia and the sensitivity of one-time screening with a fecal occult-blood test plus (...) for fecal occult blood, the relative risk of advanced neoplasia in subjects who had a positive test was 3.47 (95 percent confidence interval, 2.76 to 4.35). Sigmoidoscopy identified 70.3 percent of all subjects with advanced neoplasia. Combined one-time screening with a fecal occult-blood test and sigmoidoscopy identified 75.8 percent of subjects with advanced neoplasia.One-time screening with both a fecal occult-blood test with rehydration and sigmoidoscopy fails to detect advanced colonic neoplasia

2001 NEJM

14. Which colon cancer screening test: a comparison of costs, effectiveness, and compliance

Which colon cancer screening test: a comparison of costs, effectiveness, and compliance Which colon cancer screening test: a comparison of costs, effectiveness, and compliance Which colon cancer screening test: a comparison of costs, effectiveness, and compliance Vijan S, Hwang E W, Hofer T P, Hayward R A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several strategies for colon cancer screening were examined. These were faecal occult blood testing (FOBT) alone, FOBT combined with flexible sigmoidoscopy, flexible sigmoidoscopy alone, and colonoscopy. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised the general population of patients aged older

2001 NHS Economic Evaluation Database.

15. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. (PubMed)

Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. Although tests for occult blood in the feces are widely used to screen for colorectal cancers, there is no conclusive evidence that they reduce mortality from this cause. We evaluated a fecal occult-blood test in a randomized trial and documented its effectiveness.We randomly assigned 46,551 participants 50 to 80 years of age to screening for colorectal cancer once a year (...) specimen. Differences in mortality from colorectal cancer, the primary study end point, were monitored with the sequential log-rank statistic.The 13-year cumulative mortality per 1000 from colorectal cancer was 5.88 in the annually screened group (95 percent confidence interval, 4.61 to 7.15), 8.33 in the biennially screened group (95 percent confidence interval, 6.82 to 9.84), and 8.83 in the control group (95 percent confidence interval, 7.26 to 10.40). The rate in the annually screened group

Full Text available with Trip Pro

1993 NEJM Controlled trial quality: uncertain